Further strengthens Poolbeg’s global intellectual property portfolio 20 November 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read more…
How can companies with promising science secure the capital they need to develop drugs What does pharma need to fill their pipelines as they look to negotiate looming patent cliffs London, UK, 7 October 2025: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will be hosting its 17th Annual Healthcare Investor Conference on Thursday 9 October […]
Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Read more…
Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres 25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to […]
At 12 months, mean eGFR was 51.5 mL/min/1.73m2 in the imlifidase arm versus 19.3 mL/min/1.73m2 in the control arm with a statistically significant and clinically meaningful difference of 32.2 mL/min/1.73m2 ( p<0.0001) Imlifidase was generally well tolerated with a safety profile consistent with previous clinical trial experience Submission of a Biologic License Application (BLA) under accelerated approval pathway […]
